• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Devyser Diagnostics

86.70 SEK

-2.80 %

Less than 1K followers

DVYSR

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-2.80 %
-3.56 %
+8.92 %
-24.08 %
-21.18 %
-24.21 %
+13.19 %
-
-2.58 %

Devyser Diagnostics develops, manufactures, and sells genetic tests to laboratories globally. The products are used for DNA tests in oncology, transplantation, and hereditary diseases to enable tailored cancer treatment, diagnosis of a large number of genetic diseases, and follow-up of transplant patients. The company is headquartered in Hägersten.

Read more
Market cap
1.46B SEK
Turnover
957.47K SEK
Revenue
250.5M
EBIT %
4.03 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20/7
2026

Interim report Q2'26

3/11
2026

Interim report Q3'26

16/2
2027

Annual report '26

Regulatory press release5/22/2026, 6:30 AM

Devyser stärker ledningsgruppen - Niklas Axelsson utses till ny CFO och Sabina Berlin övergår till ny roll inom bolaget

Devyser Diagnostics
Regulatory press release5/22/2026, 6:30 AM

Devyser strengthens its executive management team – Niklas Axelsson appointed new CFO and Sabina Berlin transitions to a new role within the company

Devyser Diagnostics
Regulatory press release5/6/2026, 11:30 AM

Kommuniké från årsstämma i Devyser Diagnostics AB (publ) den 6 maj 2026

Devyser Diagnostics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/6/2026, 11:30 AM

Bulletin from the Annual General Meeting of Devyser Diagnostics AB (publ) held on 6 May 2026

Devyser Diagnostics
Devyser Diagnostics, Audiocast, Q1'26
Webcast4/27/2026, 9:00 AM

Devyser Diagnostics, Audiocast, Q1'26

Devyser Diagnostics
Regulatory press release4/27/2026, 7:00 AM

Devyser Diagnostics AB publicerar kvartalsrapport för januari till mars 2026

Devyser Diagnostics
Regulatory press release4/27/2026, 7:00 AM

Devyser Diagnostics AB publishes quarterly report for the period January to March 2026

Devyser Diagnostics
Press release4/22/2026, 7:00 AM

Inbjudan till audiocast för Devysers Q1-rapport 2026

Devyser Diagnostics
Press release4/22/2026, 7:00 AM

Invitation to audiocast for Devyser’s Q1 report 2026

Devyser Diagnostics
Press release4/7/2026, 5:50 AM

Devyser meddelar att Chief Commercial Officer lämnar bolaget

Devyser Diagnostics
Press release4/7/2026, 5:50 AM

Devyser announces that Chief Commercial Officer will leave the company

Devyser Diagnostics
Regulatory press release4/2/2026, 11:00 AM

Kallelse till årsstämma 2026 i Devyser Diagnostics AB (publ)

Devyser Diagnostics
Regulatory press release4/1/2026, 8:15 AM

Devyser fullgör förvärvet av CyberGene AB och genomför emission av vederlagsaktier

Devyser Diagnostics
Regulatory press release4/1/2026, 8:15 AM

Devyser completes acquisition of CyberGene AB and carries out issue of compensation shares

Devyser Diagnostics
Press release3/25/2026, 9:00 AM

Devyser publishes annual report for 2025

Devyser Diagnostics
Press release3/25/2026, 9:00 AM

Devyser publicerar årsredovisning för 2025

Devyser Diagnostics
Intervju med Devysers CFO under SCF:s 17:e Kapitalmarknadsdag Life Science6:31
Video3/19/2026, 7:06 AM by
Isa Hudd

Intervju med Devysers CFO under SCF:s 17:e Kapitalmarknadsdag Life Science

Devyser presenterade på Stockholm Corporate Finance 17:e kapitalmarknadsdagar Life Science 2026. Vi intervjuade CFO Sabina Berlin.

Devyser Diagnostics
Devyser Diagnostics, Investor Day, Stockholm Corporate Finance Life Science Seminarium 2026
Webcast3/18/2026, 8:30 AM

Devyser Diagnostics, Investor Day, Stockholm Corporate Finance Life Science Seminarium 2026

Devyser Diagnostics
Stockholm Corporate Finance 17:e Kapitalmarknadsdagar — Life Science 2026 │ 18:e mars
Webcast3/18/2026, 7:00 AM

Stockholm Corporate Finance 17:e Kapitalmarknadsdagar — Life Science 2026 │ 18:e mars

Välkommen att lyssna på Stockholm Corporate Finance 17:e Kapitalmarknadsdagar — Life Science 2026 │ 18:e mars.

Miris HoldingDevyser DiagnosticsOrtomaNextCell PharmaSaniona
Press release3/4/2026, 9:00 AM

Devyser launches the first IVDR compliant NGS assay for thalassemia and sickle cell disease testing

Devyser Diagnostics